Dendritic cells engineered to express the Flt3 ligand stimulate type I immune response, and induce enhanced cytoxic T and natural killer cell cytotoxicities and antitumor immunity

This publication has 59 references indexed in Scilit:

• DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice
  The Journal of Immunology, 2000
• Dendritic cells and the control of immunity
  Nature, 1998
• Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
  Nature Medicine, 1998
• Time-dependent maturation of cationic liposome–DNA complex for serum resistance
  Gene Therapy, 1998
• Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
  International Journal of Cancer, 1997
• Origin, maturation and antigen presenting function of dendritic cells
  Current Opinion in Immunology, 1997
• STK-1, the human homolog of Flk-2/Flt-3, is selectively expressed in CD34+ human bone marrow cells and is involved in the proliferation of early progenitor/stem cells.
  Proceedings of the National Academy of Sciences, 1994
• Molecular cloning of a ligand for the flt3flk-2 tyrosine kinase receptor: A proliferative factor for primitive hematopoietic cells
  Cell, 1993
• Dendritic Cells: Antigen Presentation, Accessory Function and Clinical Relevance
  Published by Springer Nature ,1993
• The Dendritic Cell System and its Role in Immunogenicity
  Annual Review of Immunology, 1991